— Advanced Radiofrequency Treatment Improves Local Circulation in Vaginal Tissue —

MARLBOROUGH, Mass., July 11, 2018  /PRNewswire/ — Hologic’s (Nasdaq: HOLX) Cynosure division announced today the North American launch of TempSure Vitalia, an FDA-cleared and Health Canada-approved advanced radiofrequency treatment. Birth control, pregnancy, hormones, and aging can change the condition of vaginal tissue over time. TempSure Vitalia delivers therapeutic heat to internal and external vaginal tissue to improve local circulation.

The TempSure Vitalia treatment, administered using a probe specifically designed for women’s genitalia, delivers precise heating for smaller, hard-to-reach areas such as vaginal and labial tissue, without hormones or the need for invasive procedures. Treatments can last between 15 and 30 minutes, depending on the treatment area, and there’s no downtime once the procedure is complete.

Unlike other radiofrequency devices, TempSure Vitalia has the distinct advantage of Therapeutic Logic Control (TLC) – a revolutionary time and temperature monitoring system that ensures treatment timing will begin only when the target tissue is at therapeutic temperature, helping deliver repeatable treatment results procedure after procedure. The device also has a unique dose counter that monitors and effectively delivers the recommended dose of radiofrequency energy to the target area.

“TempSure Vitalia responds to customers who expressed a need for a consistent and effective intimate wellness therapy that takes the guesswork out of radiofrequency treatments,” said Kevin Thornal, Hologic’s Division President, Cynosure. “It also expands the offerings on our TempSure radiofrequency platform. We are pleased that in just six months, we were able to launch an additional handpiece while simultaneously providing a solution to patients who have experienced changes in their vaginal health over time.”

In January 2018, Cynosure launched the TempSure platform with TempSure Envi, a device for minimizing fine facial lines and wrinkles, tightening the skin through soft tissue coagulation, and improving the appearance of cellulite.

To learn more about TempSure Vitalia, please visit https://www.cynosure.com/product/tempsure-vitalia/.

About Hologic, Inc.
Hologic, Inc. is an innovative medical technology company primarily focused on improving women’s health and well-being through early detection and treatment. For more information on Hologic, visit www.hologic.com.

Hologic, The Science of Sure, Cynosure and TempSure are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries.

Forward-Looking Statements
This news release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic products. There can be no assurance these products will achieve the benefits described herein or that such benefits will be replicated in any particular manner with respect to an individual patient, as the actual effect of the use of the products can only be determined on a case-by-case basis. In addition, there can be no assurance that these products will be commercially successful or achieve any expected level of sales. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such data or statements are based.

Media Contact:
Jane Mazur
508.263.8764 (direct)
585.355.5978 (mobile)
jane.mazur@hologic.com

Investor Contact:
Michael Watts
858.410.8588
michael.watts@hologic.com

Cision View original content with multimedia:http://www.prnewswire.com/news-releases/hologics-cynosure-division-launches-tempsure-vitalia-in-north-america-300678875.html

SOURCE Hologic, Inc.